Henry Schein

HSIC · NASDAQ

$84.68+$0.71 (+0.85%)TodayMarket closed ·
Prev close $83.97

HSIC analyst rating

BuyConsensus of 14 analysts over the last 12 months. 57% rate it a buy.
  • Strong buy0
  • Buy8
  • Hold5
  • Underperform1
  • Sell0

12-month price target · 19 analysts

Average $98.74 (+16.6% upside)

Low
$64.64
Now
$84.68
High
$115.50

Upgrades and downgrades

The latest rating actions, newest first

HSIC analyst upgrades, downgrades and rating actions
FirmDateActionRating
Leerink PartnersOct 14, 2026MaintainsMarket Perform
BTIGAug 19, 2026MaintainsBuy
BarclaysAug 6, 2026MaintainsOverweight
UBSAug 5, 2026MaintainsNeutral
CitigroupAug 5, 2026MaintainsBuy
BTIGAug 5, 2026MaintainsBuy
Piper SandlerJul 29, 2026MaintainsOverweight
UBSJul 28, 2026MaintainsNeutral
BMO CapitalJul 9, 2026InitiatesMarket Perform
BTIGJun 11, 2026UpgradeNeutral → Buy

The case for and against

Updated Oct 7, 2026

Bull case

  • Henry Schein is viewed positively because its core dental business is reaccelerating, with 1Q:26 U.S. Dental local internal growth of +4.1% y/y versus declines in 2024A and only +1.3% in 2025A, suggesting customers are regaining trust after the 2023 cybersecurity incident.
  • Its scale, leading market share, and sticky software-driven customer relationships support durable demand, while cloud-based users rose +25% y/y in 1Q:26 and the company benefits from a broad, high-quality dental TAM that is resilient and habit-driven.
  • Fundamentals are further strengthened by margin improvement under BOLD+1, including a 1Q:26 adjusted EBITDA margin of 8.6% (+41 bps y/y), about $200M of annual cost savings targeted, and a shift toward higher-margin high-growth businesses that should support earnings growth.

Bear case

Henry Schein is facing a muted fundamental profile because 2026E growth is still modest, with revenue modeled at $13.7B and only +3.7% y/y growth, while adjusted EBITDA is expected to rise just +4% to $1,145M, both slightly behind consensus. Demand in its core dental and medical channels appears vulnerable to geopolitical uncertainty, slower consumer confidence, and weaker reimbursement, which could cause patients to delay care and practices to reduce purchases, while the company’s service-heavy model and dependence on third-party suppliers add execution risk. It also remains exposed to competitive pressure from larger distributors and cyber disruptions, and the repeated attacks in October and November 2023 underscore the operational and reputational downside if systems are hit again.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.